Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients

Clinical Transplantation

Volumn 11, Issue 3, 1997, Pages 225-230

  Hohage, H ^a   Arlt, M ^a   Bruckner D ^a   Dietl, K H ^a   Zidek, W ^b   Spieker, C ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cardiovascular risk factors; Cyclosporin A; FK 506; Lipid metabolism; Tacrolimus

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; STEROID; TACROLIMUS;

AGE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; LIPID METABOLISM; PRIORITY JOURNAL; SEX RATIO; STATISTICS;

ADULT; AGE FACTORS; ARTERIOSCLEROSIS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYCLOSPORINE; FASTING; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPID METABOLISM; LIPIDS; MALE; PREDNISOLONE; RISK FACTORS; SEX FACTORS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TRIGLYCERIDES;

EID: 0030997848     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. IBELS LS, STEWART JH, MAHONY JF, SHEIL AGR. Deaths from occlusive arterial disease in renal allograft recipients. Br Med J 1974: 3: 552
2. KASISKE BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988: 84: 985.
3. BRUNNER FP, BROYER M, BRYNGER H, et al. Survival on renal replacement therapy: Data from EDTA registry. Nephrol Dial Transpl 1988: 2: 109.
4. KASISKE BL. The effects of immunosuppressive agents on plasma lipoproteins after organ transplantation. J Lab Clin Med 1994: 124: 318.
5. MCGRATH BP, LEDINGHAM JGG. Cardiovascular complication after renal transplantation. In: MORRIS PJ, ed. Kidney Transplantation. Principles and Practice. New York, NY: Grune & Stratton, 1979: 313.
6. CATTRAN DC, STEINER G, WILSON DR, FENTON SSA. Hyperlipidemia after renal transplantation: Natural history and pathophysiology. Ann Intern Med 1979: 91: 554.
7. RAINE AEG, CARTER R, MANN JL, MORRIS PJ. Adverse impact of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transpl 1988: 3: 458.
8. KASISKE BL, TORTORICE KL, HEIM-DUTHOY KL, AWNI WM, RAO KV. The adverse impact of cyclosporine in serum lipids in renal transplant recipients. Am J Kidney Dis 1991: 17: 700.
9. CANAFAX DM, SIMMONS RL, SUTHERLAND DER, et al. Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporin versus anti-lymphocyte globulin-azathioprine. Transpl Proc 1986: 18(Suppl.1): 192.
10. CHAN MK, VARGHESE Z, PERSAUD JW, FERNANDO ON, MOORHEAD JF. The role of multiple pharmacotherapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol 1981: 15: 309.
11. JACKSON JM, LEE HA. The role of propanolol therapy and proteinuria in the etiology of post renal transplantation hyperlipidemia. Clin Nephrol 1982: 18: 95.
12. SANDKAMP M, FUNKE H, SCHULTE H, KOHLER E, ASSMANN G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990: 36: 20.
13. RATH M, NEONDORF A, REBLIN T, DIETEL M, KREBBER HJ, BEISIEGEL U. Detection and qualification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989: 9: 579.
14. MILES LA, FLESS GM, LEVIN EG, SCANU AM, PLOW EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature (London) 1989: 339: 301.
15. WEBB AT, REAVELEY DA, O'DONNELL M, O'CONNOR B, SEED M, BROWN EA. Does cyclosporin increase lipoprotein-(a) concentrations in renal transplant recipients. Lancet 1993: 341: 268.
16. STARZL TE, TODO S, FUNG J, DEMETRIS AJ, VENKATARAMANAN R. FK 506 for liver, kidney, pancreas transplantation. Lancet 1989: 2: 1000.
17. KINO T, HATANAKA H, MIYATA S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot Tokyo 1987: 40: 1256.
18. KINO T, HATANAKA H, HASHIMOTO M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, physico-chemical and biological characteristics. J Antibiot Tokyo 1987: 40: 1249.
19. ZEEVI A, DUQUESNOY R, EIRAS G, et al. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporin A. Transpl Proc 1987: 19: 40.
20. GOTO T, KINO T, HATANAKA H, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transpl Proc 1987: 19: 4.
21. SHAPIRO R, JORDAN M, SCANTLEBURY V, et al. FK 506 on clinical kidney transplantation. Transpl Proc 1991: 23: 3065.
22. STARZL TE, FUNG J, JORDAN M, et al. Kidney transplantation uder FK 506. J Am Med Ass 1990: 264: 63.
23. DURRINGTON PN. AnonymousHyperlipidaemia. Diagnosis and management. London: Wright, 1989: 71.
24. TAMURA K, KOBAYASHI M, HASHIMOTO K, et al. A highly sensitive method to assay FK 506 levels in plasma. Transpl Proc 1987: 19 (Suppl.6): 23.
25. BROWN JH, ANWAR N, SHORT CD, et al. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transpl 1993: 8: 863.
26. SCHORN TF, KLIEM V, BOJANOVSKI M, et.al. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transpl Int 1991: 4: 92
27. TODO S, DEMETRIS A, UEDA Y, et.al. Renal transplantation in baboons under FK 506 immunosuppression. Surgery 1989: 106: 444
28. MASSY ZA, BADER GA, CHEVALIER A, et al. Serum lipoprotein-(a) levels in chronic renal failure and renal transplant patients. J Nephrol 1994: 7: 229.
29. BALLANTYNE CM, PODET EJ, PATSCH WP, et al. Effect of cyclosporin therapy on plasma lipoprotein levels. J Am Med Ass 1989: 262: 53.
30. STEINMÜLLER TM, GRAF KJ, SCHLEICHER J, et al. The effect of FK 506 versus Cyclosporine on glucose and lipid metabolism-a randomized trial. Transplantation 1994: 58: 669.
31. JINDAL RM, POPESCU I, EMRE S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK 506. Transplantation 1994: 57: 1395.
32. KRENTZ AJ, CRAMB R, DOUSSET B, et al. Serum lipids and apolipoproteins in liver transplant recipients: A comparative study of cyclosporin A and FK 506. J Lab Clin Med 1994: 124: 381.
33. PRINCE HMG, MEIJER P, HOFSTEE B, HAVEKES LM, KUIPERS F, VONK RJ. Effects of cyclosporin A on LDL-receptor activity and bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat. Hepatology 1987: 7: 1109 (Abstract).
34. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O'NEIL J, SKIBINSKI CI, HOFF HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992: 86: 475.
35. KRAFT HG, MENZEL HJ, HOPPICHLER F, VOGEL W, UTERMANN G. Changes of genetic apoprotein phenotypes caused by liver transplantation: implications for apolipoprotein synthesis. J Clin Invest 1989: 83: 137.
36. KANDOUSSI A, CACHERA C, PAGNIEZ D, DRACON M, FRUCHART JC, TACQUET A. Plasma levels of lipoprotein LP(a) is high in predialysis or hemodialysis, but not in CAPD. Kidney Int 1992: 42: 424.
37. BLACK IW, WILKEN DEL. Decreases in apolipoprotein (a) in renal transplantation: Implications for lipoprotein (a) metabolism. Clin Chem 1992: 38: 353.
38. THOMAS ME, FREESTONE A, VARGHESE Z, PERSAUD JW, MOORHEAD JF. Lipoprotein (a) in patients with proteinuria. Nephrol Dial Transplant 1992: 7: 597.
39. BARBAGALLO CM, AVERNA MR, SPARACINO V, et al. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993: 64: 560.
40. KEHELY A, BARBIR M, TAMUGAR E, et al. High prevalence of raised levels of Lp (a) and apoB after cardiac transplantation. Atherosclerosis 1990: 85: 97
41. CERIELLO A, PIRISI M, GIACOMELLO R, et al. Fibrinogen plasma levels as a marker of thrombin activation: New insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 1994: 71: 593.
42. VANRENTERGHEM Y, ROELS L, LERUT T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985: 1: 999.
43. MURPHY BG, YONG A, BROWN JH, MCNAMEE PT. Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Atherosclerosis 1995: 116: 241.
44. ZIMMERMAN J, FAINARU M, EISENBERG S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins. A prospective study. Metabolism 1984: 33: 521.
45. HRICIK DE, BARTUCCI MR, MAYES JT, SCHULAK JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992: 54: 868.